260 related articles for article (PubMed ID: 20883490)
1. Impact of medical therapy on transurethral resection of the prostate: two decades of change.
Izard J; Nickel JC
BJU Int; 2011 Jul; 108(1):89-93. PubMed ID: 20883490
[TBL] [Abstract][Full Text] [Related]
2. Impact of medical therapy on transurethral resection of the prostate: a decade of change.
Borth CS; Beiko DT; Nickel JC
Urology; 2001 Jun; 57(6):1082-5; discussion 1085-6. PubMed ID: 11377312
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
4. Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate.
Ingimarsson JP; Isaksson HJ; Sigbjarnarson HP; Gudmundsson J; Geirsson G
Scand J Urol; 2014 Feb; 48(1):73-8. PubMed ID: 23924152
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bipolar transurethral resection of the prostate with standard transurethral prostatectomy: shorter stay, earlier catheter removal and fewer complications.
Starkman JS; Santucci RA
BJU Int; 2005 Jan; 95(1):69-71. PubMed ID: 15638897
[TBL] [Abstract][Full Text] [Related]
6. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
Roehrborn CG
BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
[TBL] [Abstract][Full Text] [Related]
7. Acute urinary retention increases the risk of complications after transurethral resection of the prostate: a population-based study.
Chen JS; Chang CH; Yang WH; Kao YH
BJU Int; 2012 Dec; 110(11 Pt C):E896-901. PubMed ID: 23035623
[TBL] [Abstract][Full Text] [Related]
8. Use of Medical Therapy and Success of Laser Surgery and Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia.
Strope SA; Vetter J; Elliott S; Andriole GL; Olsen MA
Urology; 2015 Dec; 86(6):1115-22. PubMed ID: 26375848
[TBL] [Abstract][Full Text] [Related]
9. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
Vela-Navarrete R; Gonzalez-Enguita C; Garcia-Cardoso JV; Manzarbeitia F; Sarasa-Corral JL; Granizo JJ
BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526
[TBL] [Abstract][Full Text] [Related]
10. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia?
Mishra VC; Allen DJ; Nicolaou C; Sharif H; Hudd C; Karim OM; Motiwala HG; Laniado ME
BJU Int; 2007 Aug; 100(2):327-31. PubMed ID: 17617139
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
DiSantostefano RL; Biddle AK; Lavelle JP
BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
[TBL] [Abstract][Full Text] [Related]
12. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
[TBL] [Abstract][Full Text] [Related]
13. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
14. Urodynamic impact of acute urinary retention in patients with benign prostatic hyperplasia: a 2-year follow-up after transurethral resection of the prostate.
Wagenlehner FM; Bescherer K; Wagenlehner C; Zellner M; Weidner W; Naber KG
Urol Int; 2011; 86(1):73-9. PubMed ID: 20689259
[TBL] [Abstract][Full Text] [Related]
15. A multiinstitutional study of the effects of medical therapy for lower urinary symptoms on the perioperative outcomes of holmium laser enucleation of the prostate.
Warner JN; Nunez RN; Tyson MD; Viprakasit DP; Miller NL; Humphreys MR
Urology; 2011 Dec; 78(6):1385-90. PubMed ID: 21871654
[TBL] [Abstract][Full Text] [Related]
16. Examining the 'gold standard': a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes.
Mayer EK; Kroeze SG; Chopra S; Bottle A; Patel A
BJU Int; 2012 Dec; 110(11):1595-601. PubMed ID: 22540956
[TBL] [Abstract][Full Text] [Related]
17. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
18. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g.
Gupta N; Sivaramakrishna ; Kumar R; Dogra PN; Seth A
BJU Int; 2006 Jan; 97(1):85-9. PubMed ID: 16336334
[TBL] [Abstract][Full Text] [Related]
19. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
[TBL] [Abstract][Full Text] [Related]
20. Treatment of benign prostatic hyperplasia.
Pinheiro LC; Martins Pisco J
Tech Vasc Interv Radiol; 2012 Dec; 15(4):256-60. PubMed ID: 23244720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
